Background
==========

Stomach cancer is the fourth most common cancer and second leading cause of cancer-related death worldwide \[[@B1]\]. *Helicobacter pylori* (*H. pylori*) is now recognized as a major risk factor for chronic gastritis and stomach cancer development \[[@B2]\]. In addition, environmental and host factors have also been shown to influence gastric carcinogenesis, and salt (sodium chloride, NaCl) and salty food are of particular importance, based on evidence from a number of epidemiological and experimental studies \[[@B3]-[@B6]\]. Thus, combined exposure to *H. pylori* infection and excessive salt intake appears to be very important for the development and progression of gastric tumors, although the detailed mechanisms, especially in terms of gene expression profiles, remain to be clarified.

High throughput microarray technology provides a powerful tool for comprehensive gene analysis, already applied to assess gene expression patterns in both human samples and animal models of gastric disorders \[[@B7]-[@B16]\]. Although many researchers have focused on gene expression in *H. pylori*-treated gastric cell lines \[[@B17]-[@B19]\], results in cell culture do not necessarily correlate with expression of specific genes in the *in vivo* microenvironment featuring host immune responses and stromal-epithelial interactions in cancers. Carcinogen-treated Mongolian gerbils have been used as a useful animal model of *H. pylori*-associated gastric carcinogenesis \[[@B20]-[@B24]\], and we previously reported that a synergistic interaction between *H. pylori* infection and high-salt intake accelerates chronic inflammation and tumor development in the stomachs of these animals \[[@B25],[@B26]\]. Unfortunately, there is little information available for the gerbil genome, hampering genetic and molecular analysis. Therefore, attention has focused on mouse models \[[@B12],[@B13]\], and establishment of a mouse model for stomach cancer featuring salt and *H. pylori* exposure is needed for investigations targeting genes involved in gastric carcinogenesis.

Previous microarray studies using rodent models did not distinguish and characterize expression profiles based on the interaction of *H. pylori* infection and salt intake. In the present study, we examined gene expression in the gastric mucosa in a *H. pylori*-infected and high-salt diet-treated mouse gastric tumor model by oligonucleotide microarray and found two candidate up-regulated genes including *Cd177* and *Reg3g*. We also investigated the expression of CD177 in human advanced gastric cancers by immunohistochemistry, and obtained evidence as a potential prognostic factor for stomach carcinogenesis.

Methods
=======

Inoculation with *H. pylori*
----------------------------

*H. pylori* was prepared by the same method as described previously \[[@B27],[@B28]\]. Briefly, *H. pylori* (Sydney strain 1) was inoculated on Brucella agar plates (Becton Dickinson, Cockeysville, MD, USA) containing 7% (v/v) heat-inactivated fetal bovine serum (FBS) and incubated at 37°C under microaerophilic conditions at high humidity for 2 days. Then, bacteria grown on the plates were introduced into Brucella broth (Becton Dickinson) supplemented with 7% (v/v) FBS and incubated under the same conditions for 24-h. After 24-h fasting, animals were intra-gastrically inoculated *H. pylori* (1.0 × 10^8^ colony-forming units). Before inoculation, the broth cultures of *H. pylori* were checked under a phase-contrast microscope for bacterial shape and mobility.

Animals and experimental protocol
---------------------------------

Fifty-six specific pathogen-free male, 5- or 6-week-old C57BL/6J mice (CLEA Japan, Tokyo, Japan) were used in this study. All animals were housed in plastic cages on hardwood-chip bedding in an air-conditioned biohazard room with a 12-h light/12-h dark cycle, and allowed free access to food and water throughout. The experimental design was approved by the Animal Care Committee of the Aichi Cancer Center Research Institute, and the animals were cared for in accordance with institutional guidelines as well as the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan, June 1st, 2006).

The experimental design is illustrated in Figure  [1](#F1){ref-type="fig"}A. The mice were divided into 4 groups (Groups A-D); 21, 5, 15, and 15 mice were assigned to A, B, C, and D groups, respectively, at the commencement of the experiment. Animals of Groups B and D were inoculated with *H. pylori* intra-gastrically on alternate weeks (total 7 times), while mice of the other groups were inoculated with Brucella broth alone. All mice were given *N*-methyl-*N*-nitrosourea (MNU, Sigma Chemical, St Louis, MO, USA) in their drinking water at the concentration of 120 ppm on alternate weeks (total exposure was 5 weeks). For this purpose MNU was freshly dissolved in distilled water three times per week. Mice of Groups C and D received CE-2 diets (basal sodium content of 0.36%; CLEA Japan) containing 10% NaCl. During the exposure period, one animal of Group B, one of Group C and six of Group D died or became moribund and they were excluded from the experiment. At 40 weeks, the remained animals were subjected to deep anesthesia and laparotomy with excision of the stomach.

![**Experimental design and histopathological findings. A**: Experimental design. Five- to six-week-old male C57BL/6J mice were inoculated with *H. pylori* SS1 strain (Groups B and D) or Brucella broth (Groups A and C). All animals were administered 120 ppm MNU in their drinking water on alternate weeks (total exposure, 5 weeks). Mice of Groups C and D were given basal diet (CE-2) containing 10% NaCl. **B**: Histopathological findings for MNU-induced mice gastric tumors. (a and b) Gastric adenoma in the pyloric region of an MNU-treated and *H. pylori*-infected mouse (Group B). (c and d) Gastric adenocarcinoma observed in Group B. Note the high cell density and cellular and structural atypia. Bar = 200 (a and c) or 100 μm (b and d).](1471-230X-13-122-1){#F1}

Histological evaluation
-----------------------

For histological examination, the stomachs were fixed in 10% neutral-buffered formalin for 24-h, sliced along the longitudinal axis into strips of equal width, and embedded in paraffin. Four-μm thick sections were prepared and stained with hematoxylin and eosin (H&E) for histological observation. Tumors were classified into adenoma and adenocarcinoma based on cellular and morphological atypia and invasive growth to submucosa as we reported previously \[[@B21]\].

RNA preparation and oligonucleotide microarray analysis
-------------------------------------------------------

Total RNA was extracted from the whole gastric mucosa including both tumor and peripheral tissue using an RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) and its quality checked with a microchip electrophoresis system (i-chip SV1210; Hitachi Chemical, Tokyo, Japan). High-quality samples were selected, and pooled for each group to avoid individual difference for oligonucleotide microarray assessment (Group A, n = 3; B, n = 4; C, n = 6; D, n = 7). The CodeLink Mouse Whole Genome Bioarray (Applied Microarrays, Tempe, AZ, USA) containing 35,587 probe sets per chip was used to analyze gene expression profiles. Hybridization, processing, and scanning were performed by Filgen, Inc. (Nagoya, Japan), scan data images being analyzed using a software package (Microarray Data Analysis Tool, Filgen). Complete-linkage hierarchical clustering was also examined on the four groups using a qualified probe subset (Filgen).

Quantitative real-time RT-PCR of expression profiles in mice stomach
--------------------------------------------------------------------

Relative quantitative real-time RT-PCR was performed using a StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with the mouse-specific glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) gene as an internal control. After DNase treatment, first strand cDNAs were synthesized from total RNA using a SuperScript VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA). The PCR was accomplished basically following the manufacturer\'s instructions using a QuantiTect SYBR Green PCR Kit (Qiagen). The primer sequences for each gene are listed in Table  [1](#T1){ref-type="table"}. Specificity of the PCR reactions was confirmed using a melt curve program provided with the StepOne software and electrophoresis of the PCR samples in 3% agarose gels. The expression levels of mRNAs were normalized to the mRNA level of *Gapdh* and compared with the control mice (Group A) by the ΔΔCT method.

###### 

Primer sequences for relative quantitative real-time RT-PCR

            **Gene**                  **Sequences**          **Product length**   **Accession no.**
  ---------------------------- ---------------------------- -------------------- -------------------
            *Gapdh*             5′-AACGGATTTGGCCGTATTG-3′           140               NM_008084
   5′-TTGCCGTGAGTGGAGTCATA-3′                                                    
            *Cd177*             5′-AGGGGTGCCACTCACTGTTA-3′          128               NM_026862
   5′-CCGATTGTTTTGGAGTCACC-3                                                     
            *Reg3g*             5′-GTATGGATTGGGCTCCATGA-3′          106               NM_011260
   5′-GATTCGTCTCCCAGTTGATG-3′                                                    
            *Muc13*             5′-CCTAATCCCTACGCAAACCA-3′          124               NM_010739
   5′-TCTGCCCATTTCTCCTTGTC-3′                                                    

*Gapdh* glyceraldehyde-3-phosphate dehydrogenase, *Reg3g* regenerating islet-derived protein 3 gamma, *Muc13* mucin 13.

Patients and tumor specimens
----------------------------

A total of 55 cases of primary advanced gastric cancer, surgically resected at Aichi Cancer Center Hospital (Nagoya, Japan) between 1995 and 2002, were investigated after obtaining informed consent. The study was approved by the ethics committee of Aichi Cancer Center. The patients were all male and the mean age and median follow-up period were 58.6 ± 10.2 years and 83 weeks, respectively. None had received preoperative chemotherapy or radiotherapy. Carcinomas with adjacent mucosa tissue were fixed and embedded in paraffin, and sectioned for staining with H&E. Classification of tumor staging and diagnosis of advanced cases were made according to the Japanese Classification of Gastric Carcinomas \[[@B29]\]. The cancers had invaded the muscularis propria (T2 for TNM classification), the subserosa (T3), or the serosa and the peritoneal cavity (T4a), sometimes involving adjacent organs (T4b).

Immunohistochemistry using human gastric cancer tissue
------------------------------------------------------

We examined expression of CD177, for which a commercial primary antibody was available, in human gastric cancer tissues by immunohistochemistry. After inhibition of endogenous peroxidase activity by immersion in 3% hydrogen peroxide/methanol solution, antigen retrieval was carried out with 10 mM citrate buffer (pH 6.0) in a microwave oven for 10 min at 98°C. Then, sections were incubated with a mouse monoclonal anti-CD177 antibody (clone 4C4, diluted 1:100, Abnova, Taipei, Taiwan). Staining for CD177 was performed using a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) and binding visualized with 0.05% 3,3′-diaminobenzidine. The results of CD177 immunostaining in neoplastic cells were classified into four degrees; grade 0 (none, 0-10% of positive cells), grade 1 (weak, 10-30%), grade 2 (moderate, 30-60%), and grade 3 (strong, over 60%) based on proportion of stained cells, and cases showing moderate to strong staining were considered as positive.

Statistical analysis
--------------------

The Chi-square test with Bonferroni correction was used to assess incidences of gastric tumor. Quantitative values including multiplicity of tumor and relative expression of mRNA were represented as means ± SD or SE, and differences between means were statistically analyzed by ANOVA or the Kruskal-Wallis test followed by the Tukey test for multiple comparisons. Overall survival was estimated using the Kaplan-Meier method and the log-rank test for comparisons. Correlations between CD177 expression and clinicopathological factors were analyzed by ANOVA or Chi-square test. Multivariate analysis was performed to examine whether CD177 over-expression was an independent prognostic factor using the Cox proportional-hazards regression model. *P* values of \< 0.05 were considered to be statistically significant.

Results
=======

Incidences and multiplicities of gastric tumors
-----------------------------------------------

The effective number of mice and the observed incidences and multiplicities of gastric tumors are summarized in Table  [2](#T2){ref-type="table"}. Tumors developed in the gastric mucosa of all MNU-treated groups (Groups A-D) (Figure  [1](#F1){ref-type="fig"}B). In high-salt diet-treated groups (Groups C and D), the incidence of gastric tumor in Group D (*H. pylori*-infected; 100%) was significantly higher than that in Group C (non-infected; 50.0%) (*P* \< 0.05). In basal diet groups (Groups A and B), the incidence was also increased by *H. pylori*-infection (Group A, 61.9% and Group B, 100%), albeit without statistical significance. The multiplicities of total tumors in both *H. pylori*-infected groups (Group B, 3.3 ± 1.0 tumors/mouse and Group D, 2.6 ± 1.1) were markedly higher than those in non-infected groups (Group A, 0.9 ± 0.8 and Group C, 1.0 ± 1.2) (*P* \< 0.05). The multiplicity of gastric adenocarcinoma in Group D (2.1 ± 1.4) was slightly higher than that in Group B (1.8 ± 1.0) and significantly increased over the Group C value (0.8 ± 1.0) (*P* \< 0.05). In contrast, the multiplicities of adenomas in Groups A and D (0.1 ± 0.4 and 0.4 ± 0.5, respectively) were significantly lower than in Group B (1.5 ± 0.6) (*P* \< 0.05 and 0.01).

###### 

Incidence and multiplicity of gastric tumors in MNU-treated mice

   **Group**   **Effective number**  **Treatment**                   **Incidence (%)**   **Multiplicity (no. of tumor/mouse)**                                           
  ----------- ---------------------- ------------------------------ ------------------- --------------------------------------- ----------- -------------- ------------- --------------
       A                21           MNU                                  3(14.3)                      13(61.9)                  13(61.9)    0.1 ± 0.4^a^    0.8 ± 0.7     0.9 ± 0.8
       B                4            MNU + *H. pylori*                   4(100)^b^                      4(100)                    4(100)      1.5 ± 0.6      1.8 ± 1.0    3.3 ± 1.0^c^
       C                14           MNU + 10% NaCl                       2(14.3)                       6(42.9)                   7(50.0)     0.2 ± 0.6      0.8 ± 1.0     1.0 ± 1.2
       D                9            MNU + *H. pylori* + 10% NaCl         4(44.4)                       8(88.8)                  9(100)^d^   0.4 ± 0.5^e^   2.1 ±1.4^d^   2.6 ± 1.1^d^

Values for multiplicity are expressed as means ± SD. Incidences were generally assessed by Chi-square test, followed by pairwise analysis with Bonferroni correction. Multiplicities were generally analyzed by ANOVA, followed by the Tukey test for multiple comparison. ^a^*P* \< 0.01 *vs.* Group B, ^b^*P* \< 0.01 *vs.* Group A, ^c^*P* \< 0.05 *vs.* Group A, ^d^*P* \< 0.05 *vs.* Group C, ^e^*P* \<0.05 *vs.* Group B.

Gene expression profiling in the glandular stomachs by oligonucleotide microarray
---------------------------------------------------------------------------------

With oligonucleotide microarrays, compared with the non-infected and basal diet-treated group (Group A), 34 genes were up-regulated and 169 were down-regulated more than two-fold in *H. pylori*-infected mice (Group B), 56 up-regulated and 129 down-regulated in high-salt diet-treated mice (Group C), and 69 up-regulated and 214 down-regulated in the combined group (Group D) (Figure  [2](#F2){ref-type="fig"}A). Taken together, as shown in Table  [3](#T3){ref-type="table"}, we found that 35 genes were up-regulated and 31 genes were down-regulated more than two-fold only by the combination of *H. pylori* infection and high-salt diet. In addition, hierarchical clustering analysis was performed on the four groups with a total of 303 qualified probes using the complete-linkage clustering algorithm (Figure  [3](#F3){ref-type="fig"}). Thirty-one probes including *Cd177*, *Reg3g* and *Muc13* were confirmed to be within a cluster of probes up-regulated only in Group D. Subsequent analysis in the present study was focused on these genes, because it was considered that the genes in which expression was altered only in the combined group might be associated with gastric carcinogenesis and progression in humans.

![**Global gene analysis in the glandular stomach of MNU-treated mice using oligonucleotide microarray. A**: Number of genes up- or down-regulated more than two-fold in the stomach of MNU-treated mice. In Venn's diagram, the circles indicate up- (left) or down-regulated (right) genes in the stomach of MNU-treated mice with *H. pylori* infection, high-salt diet or their combination. The shaded area represents the up- or down-regulated genes more than two-fold only by the combination. **B**: Quantitative real-time RT-PCR analysis of three selected up-regulated genes (*Cd177*, *Reg3g*, and *Muc13*) in the stomachs of MNU-treated mice. Expression levels of the genes in each sample were normalized by *Gapdh* as internal control using ΔΔCT method. Relative expression levels were represented as the X-fold change relative to Group A (fixed as 1.0). Statistical analysis was performed by the Kruskal-Wallis test for general analysis and Tukey test for multiple comparison. Bars, SE; \*, *P* \< 0.01 *vs.* Group A and \< 0.05 *vs.* Group C; †, *P* \< 0.01 *vs.* Group C.](1471-230X-13-122-2){#F2}

###### 

**Regulated genes by combination of*H. pylori*infection and high-salt diet in mouse gastric mucosa**

  **Accession no.**        **Symbol**   **Genes/proteins**                                                          **Fold changes**
  ------------------------ ------------ ------------------------------------------------------------------------- ------------------
  *Up-regulated genes*                                                                                            
  XM_357640                Igk-V8       Immunoglobulin kappa chain variable 8 (V8)                                              14.4
  XM_001472541             Ighg         Immunoglobulin heavy chain (gamma polypeptide)                                           9.2
  NM_026862                Cd177        CD177 antigen                                                                            7.3
  NM_011260                Reg3g        Regenerating islet-derived 3 gamma                                                       6.1
  NM_023137                Ubd          Ubiquitin D                                                                              4.3
  XM_144817                Igk-V34      Immunoglobulin kappa chain variable 34 (V34)                                             4.1
  NM_007675                Ceacam10     Carcinoembryonic antigen-related cell adhesion molecule 10                               3.7
  NM_183322                Khdc1a       KH domain containing 1A                                                                  3.3
  NM_011475                Sprr2i       Small proline-rich protein 2I                                                            3.2
  NM_175165                Tprg         Transformation related protein 63 regulated                                              3.2
  NM_175406                Atp6v0d2     ATPase, H+ transporting, lysosomal V0 subunit D2                                         3.0
  NM_009703                Araf         v-raf murine sarcoma 3611 viral oncogene homolog                                         2.6
  NM_026822                Lce1b        Late cornified envelope 1B                                                               2.5
  NM_016958                Krt14        Keratin 14                                                                               2.5
  NM_212487                Krt78        Keratin 78                                                                               2.4
  NM_009807                Casp1        Caspase 1                                                                                2.4
  NM_146037                Kcnk13       Potassium channel, subfamily K, member 13                                                2.4
  NM_019450                Il1f6        Interleukin 1 family, member 6                                                           2.3
  NM_008827                Pgf          Placental growth factor                                                                  2.3
  XM_893506                Klk12        Kallikrein related-peptidase 12                                                          2.3
  NM_016887                Cldn7        Claudin 7                                                                                2.3
  NM_029360                Tm4sf5       Transmembrane 4 superfamily member 5                                                     2.2
  NM_172301                Ccnb1        Cyclin B1                                                                                2.2
  NM_010739                Muc13        Mucin 13, epithelial transmembrane                                                       2.2
  NM_011165                Prl4a1       Prolactin family 4, subfamily a, member 1                                                2.2
  NM_010162                Ext1         Exostoses (multiple) 1                                                                   2.2
  NM_011704                Vnn1         Vanin 1                                                                                  2.1
  NM_011082                Pigr         Polymeric immunoglobulin receptor                                                        2.1
  NM_007769                Dmbt1        Deleted in malignant brain tumors 1                                                      2.1
  NM_022984                Retn         Resistin                                                                                 2.1
  NM_173037                Tmco 7       Transmembrane and coiled-coil domain 7                                                   2.1
  NM_009100                Rptn         Repetin                                                                                  2.1
  NM_007630                Ccnb2        Cyclin B2                                                                                2.1
  NM_001081060             Slc9a3       Solute carrier family 9 (sodium/hydrogen exchanger), member 3                            2.0
  NM_146588                Olfr1030     Olfactory receptor 1030                                                                  2.0
  *Down-regulated genes*                                                                                          
  NM_008753                Oaz1         Ornithine decarboxylase antizyme 1                                                      0.31
  NM_027126                Hfe2         Hemochromatosis type 2 (juvenile) (human homolog)                                       0.33
  NM_053206                Magee2       Melanoma antigen, family E, 2                                                           0.33
  NM_010924                Nnmt         Nicotinamide N-methyltransferase                                                        0.41
  NM_026260                Tctn3        Tectonic family member 3                                                                0.41
  NM_181039                Lphn1        Latrophilin 1                                                                           0.43
  NM_008312                Htr2c        5-hydroxytryptamine (serotonin) receptor 2C                                             0.43
  NM_146667                Olfr740      Olfactory receptor 740                                                                  0.44
  NM_007550                Blm          Bloom syndrome homolog (human)                                                          0.44
  NM_011243                Rarb         Retinoic acid receptor, beta                                                            0.44
  NM_184052                Igf1         Insulin-like growth factor 1                                                            0.45
  NM_013893                Reg3d        Regenerating islet-derived 3 delta                                                      0.46
  NM_008645                Mug1         Murinoglobulin 1                                                                        0.46
  NM_029550                Keg1         Kidney expressed gene 1                                                                 0.46
  NM_019388                Cd86         CD86 antigen                                                                            0.46
  NM_011316                Saa4         Serum amyloid A 4                                                                       0.47
  NM_007811                Cyp26a1      Cytochrome P450, family 26, subfamily a, polypeptide 1                                  0.47
  NM_011538                Tbx6         T-box 6                                                                                 0.48
  NM_011086                Pip5k3       Phosphatidylinositol-3-phospate/phosphatidylinositol 5-kinase, type III                 0.48
  NM_133723                Asph         Aspartate-beta-hydroxylase                                                              0.48
  NM_001081390             Palld        Palladin, cytoskeletal associated protein                                               0.48
  NM_007858                Diap1        Diaphanous homolog 1 (Drosophila)                                                       0.48
  NM_053271                Rims2        Regulating synaptic membrane exocytosis 2                                               0.48
  NM_153163                Cadps2       Ca2+-dependent activator protein for secretion 2                                        0.49
  NM_007541                Bglap1       Bone gamma carboxyglutamate protein 1                                                   0.49
  NM_031871                Ghdc         GH3 domain containing                                                                   0.49
  NM_025545                Aptx         Aprataxin                                                                               0.49
  NM_177322                Agtr1a       Angiotensin II receptor, type 1a                                                        0.49
  NM_026872                Ubap2        Ubiquitin-associated protein 2                                                          0.49
  NM_028045                Erv3         Endogenous retroviral sequence 3                                                        0.49
  NM_011641                Trp63        Transformation related protein 63                                                       0.49

![**Hierarchical clustering analysis of four experimental groups of MNU-treated mice.** Expression data from 303 qualified probes (left). The four experimental groups were classified into two clusters (Groups A/C) and (Groups B/D) based on similarities in expression patterns. Each row represents a probe and each column represents a experimental group (Groups A-D). As shown in the color bar, green indicates up-regulation; red indicates down-regulation; and black indicates no change. Thirty-one probes constituted a cluster of probes up-regulated only in Group D (right).](1471-230X-13-122-3){#F3}

The entire results of this microarray analysis have been submitted and are readily retrievable from the public database NCBI Gene Expression Omnibus (GEO) with the accession number GSE29444 (sample number: GSM728857-60).

Quantitative real-time RT-PCR analysis of gene expression profiles in MNU-treated mouse stomachs
------------------------------------------------------------------------------------------------

Relative quantitative real-time RT-PCR analysis of three selected up-regulated genes (*Cd177*, *Reg3g*, and *Muc13*) in *H. pylori*-infected and high-salt diet-treated mice confirmed increased expression of *Cd177* and *Reg3g*, as shown in Figure  [2](#F2){ref-type="fig"}B, with significant differences. Although expression level of *Muc13* in Group D was higher than all other groups, there was no statistical significance among them (*P* = 0.0712 *vs.* Group C).

Immunohistochemical expression of CD177 in human advanced gastric cancers and correlation with clinicopathological factors
--------------------------------------------------------------------------------------------------------------------------

On immunohistochemical analysis of human gastric cancer tissues, CD177 was observed not only in the membranes and cytoplasms of infiltrated neutrophils, but also in gastric cancer cells of both well- and poorly-differentiated adenocarcinomas (Figure  [4](#F4){ref-type="fig"}A). Cancer cells of signet-ring cell type (2 cases) were negative for CD177. Among 55 gastric cancer cases, moderate to strong expression of CD177 was observed in 33 (60.0%) (Table  [4](#T4){ref-type="table"}).

![**Immunohistochemistry for CD177 in human advanced gastric cancer and correlation with overall survival rate. A**: Immunohistochemical analysis of CD177 expression in human gastric cancer tissue. (a and b) Negative staining (none to weak) for CD177 in a gastric adenocarcinoma. CD177 expression is present only in infiltrating neutrophils while neoplastic cells of well-differentiated (a) or poorly-differentiated (b) carcinoma are negative. Original magnification, ×100 (inset, ×400). (c and d) Note positive (moderate to strong) expression for CD177 in well-differentiated (c) or poorly-differentiated (d) gastric cancer cells. Original magnification, ×100 (inset, ×400). **B**: Comparison of Kaplan-Meier cumulative survival curves for CD177 negative and positive gastric cancer cases.](1471-230X-13-122-4){#F4}

###### 

CD177 expression in gastric carcinomas and its correlation with clinicopathological factors

                                                       **Case no.**   **CD177 Over-expression**   ***P*value‡**                              
  --------------------------------------------------- -------------- --------------------------- --------------- ------------- ------------- --------
  Gastric adenocarcinomas                                   55                   18                    15             17             5           
  Age                                                                                                                                        
    Years (means ± SD)                                                       55.3 ± 10.4           60.2 ± 8.13    59.8 ± 11.0   60.4 ± 13.0   0.5039
  Histological classification                                                                                                                
    Well/moderately-differentiated type\*                   21                    6                     9              4             2        0.1904
    Poorly-differentiated/Signet-ring cell type\*\*         34                   12                     6             13             3           
  Depth of invasion†                                                                                                                         
    T1-3                                                    27                    5                    10             10             2        0.2011
    T4                                                      26                   11                     5              7             3           
  Lymph node metastasis                                                                                                                      
    N0                                                      6                     1                     2              2             1        0.7869
    N1-3                                                    49                   17                    13             15             4           

\* Lauren's intestinal type, \*\* Lauren's diffuse type, † Case number was reduced to fifty-three because the depth of invasion was not classified in two cases, ‡ ANOVA and Chi-square test were performed for age and other factors, respectively.

The follow-up period of the patients ranged from 9 to 606 weeks (median = 83 weeks). Five-year survival rates for CD177-positive and negative were 39.4% and 18.2%, respectively. From the Kaplan-Meier survival curve analysis, CD177-positive expression was associated with better overall survival (*P* = 0.0294, log-rank test) (Figure  [4](#F4){ref-type="fig"}B). There was no statistically significant correlation of CD177 expression with age, histological classification, depth of invasion, and lymph node metastasis (Table  [4](#T4){ref-type="table"}).

Multivariate analysis for overall survival of human gastric cancer cases
------------------------------------------------------------------------

Using the Cox proportional hazards model, multivariate analysis of clinicopathological variables, including the patient age, tumor histological classification, invasion depth, lymph node metastasis, and CD177 expression (Table  [5](#T5){ref-type="table"}), revealed the last to be an independent factor for overall survival (*P* = 0.0323). Patient age and low differentiation of adenocarcinoma were also associated with poor overall survival (*P* = 0.0439 and 0.0017, respectively). Tumor invasion depth and lymph node metastasis were not independent factors of gastric cancer cases in the present study (*P* \> 0.05).

###### 

Multivariate analysis of prognostic factos in patients with gastric cancer using Cox proportional hazard model

  **Factors**                                  **Hazard ratio**   **95% CI**    ***P*value**
  ------------------------------------------- ------------------ ------------- --------------
  CD177 expression (negative)                        2.07         1.063-4.021      0.0323
  Age (year)                                         1.04         1.001-1.071      0.0439
  Histological type (poorly-differentiated)          4.06         1.695-9.742      0.0017
  Depth of invasion (high grade)                     1.64         0.790-3.410      0.1838
  Lymph node metastasis (positive)                   3.40         0.773-14.92      0.1055

Discussion
==========

In the present study, we demonstrated that the mouse model combined with *H. pylori* infection and high-salt diet is a useful tool to investigate the detailed mechanisms both of development and progression of gastric neoplasms. A number of rodent models of gastric cancer have been developed under various conditions, including *H. pylori* or *H. felis* infection, exposure to chemical carcinogens, and genetic modification \[[@B21],[@B30]\]. Since *H. pylori* is known as a most closely-associated risk factor in man, animal models with infection of the bacterium, such as that utilizing Mongolian gerbils, are considered to be particularly important to mimic the background of human gastric carcinogenesis. On the other hand, there is a consensus that gastric cancer is a multifactorial disease \[[@B31]\]. Epidemiological studies and animal experiments have demonstrated that development of stomach cancer is also associated with many other factors including salt intake, alcohol drinking and cigarette, containing a wide variety of chemical carcinogen. In the present study, we attempted to mimic the gastric environment of human high-risk group exposed to combination of *H. pylori* infection, salt intake, and carcinogen.

As might be expected, there are both advantages and disadvantages of *Helicobacter*-infected mouse models. Instability of *cag* pathogenicity islands (PAI), a particularly important virulence factor of *H. pylori*, has been reported in the mouse model using SS1 strain \[[@B32]\]. Multiplicity of gastric tumors is difficult to examine in the gerbil model, because almost all of the stomach tumors in gerbils show invasive growth into the lamina propria or muscle layer. In the present study, our results demonstrated that *H. pylori* infection increased not only incidence but also multiplicity of gastric tumors in MNU-treated mice. Thus, the mouse model presented here has advantages in respect to investigate the multiplicity and tissue sampling for gene expression analysis.

In this study, we focused on the genes in which the expression was regulated only in *H. pylori*-infection and high-salt diet combined mice, which are expected to reflect the background of human high-risk group, to explore examples which might be associated with tumor progression. The two up-regulated genes selected, *Cd177* and *Reg3g* could be confirmed to exhibit significant over-expression by relative quantitative RT-PCR. Expression level of *Muc13* showed a tendency for increase with combination of *H. pylori* and salt, although this was not statistically significant. *Muc13* is a recently identified gene encoding transmembrane mucin that is expressed in the stomach to large intestine \[[@B33]\]. Shimamura et al. have reported that overexpression of *Muc13* is associated with differentiation towards the intestinal (differentiated) type of human gastric cancer \[[@B34]\]. In addition, the combined expression of MUC13 with other metaplasia biomarkers is shown to be a prognostic indicator in several types of gastric cancer \[[@B35]\]. In the present study, all gastric tumors observed in MNU-treated mice were histologically of differentiated type. The REG protein family is also known to be associated with gastric cancer development and *Reg1α* and *Reg4* have been suggested as prognostic markers for advanced stomach cancers in man \[[@B36]\]. The present results indicate the possibility that *Reg3g* is also involved with progression of stomach tumor.

Immunohistochemical analysis of CD177 in advanced gastric cancer specimens showed expression to be significantly correlated with a good prognosis and survival rate after surgery. Importantly, multivariate analysis with clinicopathological factors as covariates further revealed high expression to be an independent prognostic factor for overall survival, as along with patient's age and histological classification. To our knowledge, the present study is the first to provide evidence that high expression of CD177 is associated with favorable prognosis in advanced gastric cancer.

CD177 is a member of the leukocyte antigen 6 (Ly-6) gene superfamily, encoding two neutrophil-associated proteins, NB1 and PRV-1 \[[@B37],[@B38]\]. The NB1 glycoprotein is typically expressed on a subpopulation of neutrophils, located at plasma membranes and secondary granules. Recent studies have demonstrated that CD177 is over-expressed in neutrophils from 95% of patients with polycythemia vera and in half of patients with essential thrombocythemia \[[@B37]\]. Gonda et al. have reported a microarray analysis that *Cd177* expression in whole gastric tissue of *H. felis*-infected mice with mucosal dysplasia is reduced by folic acid supplementation \[[@B39]\]. Because they compared stage-matched groups to detect up- or down-regulated genes only by treatment of folic acid, it is unclear if *Cd177* expression is associated with gastritis or dysplasia. In our microarray results, there were no significant differences in expression of *Ela2*, which is a neutrophil-specific gene \[[@B40]\], and histological degrees of neutrophil infiltration were almost same among *H. pylori*-infected groups (data not shown). Therefore, the up-regulation of *Cd177* observed in this study was considered to be caused not by increased infiltration of neutrophils into the gastric mucosa but by a change of gene expression in tumor cells. NB1 is similar in structure to urokinase-type plasminogen activator receptor (uPAR), which is known to be associated with cell adhesion and migration \[[@B37]\]. Thus, there is a possibility that CD177 also acts as a regulator of adhesion and migration of neoplastic cells in gastric tumor. Further studies are needed to clarify the association between CD177 expression in gastric epithelial cells and tumor progression.

Conclusions
===========

We demonstrated that the mouse model combined with *H. pylori* infection and high-salt diet is suitable for investigation of global gene expression associated with gastric tumor development and progression. Furthermore, our results suggest that CD177 expression might be associated with a favorable prognosis of gastric adenocarcinomas in man.
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